RMRossella Letizia Mancusi

Rossella Letizia Mancusi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rossella Letizia Mancusi has a total of 123 co-authors. Here are the top co-authors by number of shared publications:

  • Anna Fagotti

    Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy

    2 shared publications
  • Catherine Oppenheim

    Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, IMA-brain team, 75014 Paris, France; Department of Neuroradiology, GHU Paris Psychiatrie & Neurosciences, site Sainte-Anne, 75014 Paris, France

    2 shared publications
  • Adèle Henensal

    Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, IMA-brain team, 75014 Paris, France

    1 shared publication
  • Alessia Fossatelli

    Catholic University of the Sacred Heart, Rome, Italy

    1 shared publication
  • Alexandre Dizeux

    Institute Physics for Medicine Paris, Inserm U1273, ESPCI Paris, PSL University, CNRS UMR 8063, 75015 Paris, France

    1 shared publication
  • Alexandre Haroche

    Department of Adult Psychiatry S17-18, GHU Paris Psychiatrie & Neurosciences, site Sainte-Anne, 75014 Paris, France; Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, IMA-brain team, 75014 Paris, France

    1 shared publication

Latest Publications

  • Open Access

    Prognostic significance of lymphovascular space invasion extent across molecular classes in early-stage endometrial cancer: A large retrospective analysis

    by Ilaria Capasso, Emanuele Perrone, Rossella Letizia Mancusi, Matteo Loverro, Emilia Palmieri, Lucia Tortorella, Gian Franco Zannoni, Angela Santoro, Giovanni Esposito, Vincenzo Tarantino, et al.


  • Open Access

    Controlled Ovarian Stimulation After Fertility-Sparing Surgery for Borderline Ovarian Tumors: An Exploratory Cohort Study on Recurrence and Reproductive Outcomes

    by Sofia Thiella, Giacomo Corrado, Paola Villa, Inge Peters, Diana Giannarelli, Rossella Letizia Mancusi, Tina Pasciuto, Lucrezia Massaro, Maria Luisa Di Pietro, Maria Lucia Specchia, et al.

    Borderline ovarian tumors often affect women of reproductive age for whom fertility preservation may be a major concern. While fertility-sparing surgery is widely accepted, the safety of controlled ovarian stimulation for oocyte cryopreservation after surgery remains uncertain due to potential recurrence risk. This retrospective single-center cohort study explored the association between controlled ovarian stimulation following fertility-sparing surgery and both recurrence risk and reproductive outcomes. Patients treated between January 2011 and June 2024 were included. Baseline characteristics, surgical details, and reproductive outcomes were compared using non-parametric and exact tests. Progression-free survival was assessed with Kaplan–Meier estimates and Cox proportional hazards models, modeling stimulation as a time-dependent covariate, and using a 10-month landmark analysis to account for immortal time bias. Of 45 included patients, 19 underwent ovarian stimulation after surgery, with a median interval of 9.9 months to stimulation. Median follow-up was 34.4 months. Recurrence occurred in 21.1% of stimulated patients versus 38.5% of non-stimulated patients (p = 0.338). After adjustment for time-dependent exposure, ovarian stimulation was not associated with increased recurrence risk (HR 0.95, 95% CI 0.22–4.09; p = 0.944). Eleven patients (24.4%) achieved at least one pregnancy, 81.8% of which were spontaneous. Controlled ovarian stimulation for oocyte cryopreservation after fertility-sparing surgery for borderline ovarian tumors did not show an increased recurrence risk, although larger studies are needed.

  • Open Access

    Short-term impact of BREF-ED, an early, single-family psychoeducational programme for caregivers of individuals with eating disorders: A retrospective pilot study

    by Elisabetta Scanferla, Juliette de Salle, Johana Monthuy-Blanc, Rossella Letizia Mancusi, Louis-Ferdinand Lespine, Romain Rey, Philip Gorwood

    Background: There is an urgent need to improve early accessibility to psychoeducational interventions for informal caregivers of individuals with eating disorders (EDs). We adapted the BREF programme, a short, single-family, psycho-educational intervention originally developed for caregivers in severe mental disorders, to EDs (BREF-ED) and assessed at diagnosis announcement. We hypothesised that it has a good acceptability and effectiveness in reducing short-term caregivers’ self-reported levels of burden and depressive symptoms. Methods: Data of caregivers who participated in the BREF-ED programme were analysed. Adherence, satisfaction, and perceived usefulness were evaluated. Changes in self-reported burden and depression symptoms were measured pre-, post-, and 3 months after the intervention using the Zarit Burden Interview (ZBI) and Center for Epidemiological Studies – Depression scale (CES-D). Results: Of the 53 caregivers included in the study, 52 participants completed the BREF-ED programme. As compared to baseline, ZBI scores showed a significant reduction after the intervention (Cohen’s d = 0.61, p < 0.001), and at the 3-month assessment (Cohen’s d = 0.62, p < 0.001). The CES-D scores also significantly decreased by the end of the third session (Cohen’s d = 0.83, p < 0.001) and at the 3-month follow-up (Cohen’s d = 0.77, p < 0.001). Satisfaction scores were high, with 90.1% of participants reporting being “very satisfied” and 9.9% “satisfied.” Conclusions: Preliminary findings demonstrated high adherence rates, caregiver satisfaction, and a positive impact on burden and related depressive symptoms immediately after the programme and at short-term follow-up. This time- and resource-efficient programme has the potential for easy dissemination.


  • Top Cited Papers
    Open Access

    Deep transcranial ultrasound stimulation using personalized acoustic metamaterials improves treatment-resistant depression in humans

    by David Attali, Thomas Tiennot, Thomas J. Manuel, Maxime Daniel, Alexandre Houdouin, Philippe Annic, Alexandre Dizeux, Alexandre Haroche, Ghita Dadi, Adèle Henensal, et al.


  • Cathodal Transcranial Direct Current Stimulation in Acute Ischemic Stroke: Pilot Randomized Controlled Trial

    by Estelle Pruvost-Robieux, Joseph Benzakoun, Guillaume Turc, Angela Marchi, Rossella Letizia Mancusi, Catherine Lamy, Valérie Domigo, Catherine Oppenheim, David Calvet, Jean-Claude Baron, et al.

    Background and Purpose: In acute stroke, preventing infarct growth until complete recanalization occurs is a promising approach as an adjunct to reperfusion therapies to reduce infarct size and improve outcome. In rodent models, cathodal transcranial direct current stimulation (C-tDCS) decreases peri-infarct depolarizations and reduces infarct volume. We hypothesized that C-tDCS would nonpharmacologically reduce infarct growth in hyperacute middle cerebral artery territory stroke patients receiving reperfusion therapy. Methods: STICA (Cathodal Transcranial Direct Stimulation in Acute Middle Cerebral Artery Stroke) was a pilot single-center, double-blind, 2-arms 1:1 randomized trial evaluating the safety, feasibility, and efficacy of C-tDCS versus sham stimulation in patients eligible for recanalization therapies. Magnetic resonance imaging was obtained both on admission and 24 hours later. The primary end point was 24-hour infarct growth. Secondary outcomes were (1) National Institutes of Health Stroke Scale score difference between day 7 and admission and (2) 3-month modified Rankin Scale score. Results: Forty-five patients were randomized. Median magnetic resonance imaging-to-C-tDCS start time was 45 minutes; C-tDCS was started before completion of recanalization procedure in all patients. The intervention proved feasible in all patients. No major adverse effects occurred in either group. There was no significant difference between active and sham groups for any end point. However, an apparent trend towards smaller infarct growth in the C-tDCS arm was observed in the whole group (unadjusted median difference [IC 95% ]: −2.2 mL [−12.2 to 1.5]) and in the prespecified subsamples with moderate-to-severe stroke and large vessel occlusion (−5.7 mL [−21.6 to 2.6] and −7.7 mL [−24.2 to 2.6], respectively). Conclusions: C-tDCS was feasible and well tolerated. No significant difference was found between the active and sham groups. However, the data suggest potential benefits of C-tDCS in patients with National Institutes of Health Stroke Scale score of >10 or large vessel occlusion. Using the observed effect size and standard α=5% and β=20%, samples of 102 and 86, respectively, can be estimated for future trials in patients with these characteristics. Randomized trials particularly targeting these populations may be warranted.


  • Open Access

    Effect of early treatment with polyvalent immunoglobulin on acute respiratory distress syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a randomized controlled trial

    by Aurélien Mazeraud, Bruno Gonçalves, Philippe Aegerter, Letizia Mancusi, Christine Rieu, Fernando Bozza, Khaoussou Sylla, Shidasp Siami, Tarek Sharshar

    Background: As of mid-June 2020, 7,500,000 people were infected with SARS-CoV-2 worldwide and 420,000 people died, mainly from coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS). COVID-19-related ARDS is subject to a mortality rate of 50% and prolonged period of mechanical ventilation, with no specific pharmacological treatment currently available (Infection au nouveau Coronavirus (SARS-CoV-2), COVID-19, France et Monde. https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19). Because of its immunomodulatory action, we propose to evaluate the efficacy and safety of intravenous immunoglobulin (IVIG) administration in patients developing COVID-19-related ARDS. Methods: The trial is a phase III double-blind, randomized, multicenter, parallel group, concurrent, controlled study in hospitalized participants with COVID-19 requiring mechanical ventilation using a sequential design. Participants in the treatment group will receive infusions of polyvalent immunoglobulin for 4 consecutive days, and the placebo group will receive an equivalent volume of sodium chloride 0.9% for the same duration. The primary outcome is the number of ventilator-free days up to the 28th day. Secondary objectives are to evaluate the effect of IVIG on (1) organ failure according to the Sequential Organ Failure Assessment (SOFA) score at 14 and 28 days, (2) lung injury score at 14 and 28 days, (3) the occurrence of grade 3 or 4 adverse events of IVIG, (4) length of intensive care unit (ICU) stay, (5) length of hospital stay, (6) functional outcomes at day 90 defined by the activities of daily living and instrumental activities of the daily living scales, and (7) 90-day survival. One hundred thirty-eight subjects will be randomized in a 1:1 ratio to IVIG or placebo groups (69 in each group), considering 90% power, alpha level 0.05 (two sides), and 0.67 effect size level. Discussion: The ICAR trial investigates the effect of IVIG in COVID-19-related ARDS. We expect an increase in the survival rate and a reduction in the duration of mechanical ventilation, which is associated with significant morbidity. Trial registration: EudraCT 2020-001570-30. ClinicalTrials.gov NCT04350580. Registered on 17 April 2020


  • Meningioangiomatosis

    by Alexandre Roux, Marc Zanello, Rossella Letizia Mancusi, Megan E.H. Still, FábIo A. Nascimento, Arnault Tauziede-Espariat, Gilles Huberfeld, Gilles Zah-Bi, Edouard Dezamis, Jean-François Meder, et al.

    Background: Meningioangiomatosis is a poorly studied, rare, benign, and epileptogenic brain lesion. Objective: To demonstrate that surgical resection and a short time interval to surgery improves epileptic seizure control, we performed a systematic review and meta-analysis of meningioangiomatosis cases. Methods: Using PRISMA-IPD guidelines, the authors performed a systematic review and meta-analysis of histopathologically proven meningioangiomatosis cases. Literature search in the French and English languages (PubMed, Embase, the Cochrane Library and the Science Citation Index) including all studies (January 1981 to June 2020) dealing with histopathologically proven meningioangiomatosis, without age restriction. We assessed clinical, imaging, histomolecular, management, and outcome findings of meningioangiomatosis patients. Results: Two-hundred and seven cases of meningioangiomatosis from 78 studies were included. The majority of meningioangiomatosis was sporadic, preferentially concerned male patients, younger than 20-year-old, and allowed a functionally independent status. Epileptic seizure was the main symptom, with 81.4% of patients having uncontrolled seizures at the time of surgery. Meningioangiomatosis mainly had frontal (32.3%) or temporal (30.7%) locations. Imaging presentation was heterogeneous, and the diagnosis was often missed pre-operatively. The histopathologic pattern was similar whatever the clinical presentation, and immunohistochemistry had limited diagnostic value. On molecular analysis, allelic loss at 22q12 was more frequent in samples of meningioangiomatosis-associated meningioma (37.5%) than in isolated meningioangiomatosis (23.1%). Time interval from diagnosis to surgery (p=0.011) and lack of surgical resection of the meningioangiomatosis (p=0.009) were independent predictors of post-operative seizure control. Conclusions: Due to low scientific evidence, a multicentric prospective study should help refining the management of meningioangiomatosis.


  • Open Access

    Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program

    by Vincenza Calvaruso, Chiara Mazzarelli, Laura Milazzo, Lorenzo Badia, Luisa Pasulo, Giovanni Guaraldi, Raffaella Lionetti, Erica Villa, Vanni Borghi, Paola Carrai, et al.

    We reported the efficacy and safety data for daclatasvir (DCV)-based all-oral antiviral therapy in patients treated in the Italian compassionate-use program. 275 patients were included (202 male-73.5%, mean age: 57.4 years, 62 HIV-coinfected, 94 with recurrence of hepatitis C post-OLT). Forty-nine patients (17.8%) had Child-Pugh B, Genotype(G) distribution was: G1a:72 patients (26.2%), G1b:137 (49.8%); G3:40 (14.5%) and G4:26 (9.5%). Patients received DCV with sofosbuvir(SOF) (n = 221, 129 with ribavirin(RBV) or with simeprevir (SMV) or asunaprevir (ASU) (n = 54, 19 with RBV) for up to 24 weeks. Logistic regression was used to identify baseline characteristics associated with sustained virological response at week 12 post-treatment (SVR12). Liver function changes between baseline and follow up were assessed in 228 patients. 240 patients achieved SVR12 (87.3%), post transplant and HIV co-infected patients were equally distributed among SVR and no SVR (35% vs 34.3%; p = 0.56 and 24.2% vs 11.4%, p = 0.13, respectively). SVR rate was significantly higher with the combination DCV + SOF compared with DCV + SIM or ASU (93.2% vs 63.0%, p < 0.0001). Bilirubin value (OR: 0.69, CI95%: 0.54–0.87, p = 0.002) and regimen containing SOF (OR: 9.99, CI95%: 4.09–24.40; p < 0.001) were independently related with SVR. Mean albumin and bilirubin values significantly improved between baseline and follow-up week 12. DCV-based antiviral therapy was well tolerated and resulted in a high SVR when combined with SOF either in pre-transplant and in OLT patients and in “difficult to treat” HCV genotypes. Regimens containing DCV in combination with NS3 protease inhibitors obtained suboptimal results.